PE20050293A1 - Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos - Google Patents

Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos

Info

Publication number
PE20050293A1
PE20050293A1 PE2004000205A PE2004000205A PE20050293A1 PE 20050293 A1 PE20050293 A1 PE 20050293A1 PE 2004000205 A PE2004000205 A PE 2004000205A PE 2004000205 A PE2004000205 A PE 2004000205A PE 20050293 A1 PE20050293 A1 PE 20050293A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
methyl
case
medicines
Prior art date
Application number
PE2004000205A
Other languages
English (en)
Spanish (es)
Inventor
Hans-Ludwig Schaefer
Heiner Glombik
Dirk Gretzke
Jochen Goerlitzer
Eugen Falk
Stefanie Keil
Christian Stapper
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20050293A1 publication Critical patent/PE20050293A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PE2004000205A 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos PE20050293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20050293A1 true PE20050293A1 (es) 2005-05-24

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2004000206A PE20040959A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion
PE2004000203A PE20050292A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos
PE2004000205A PE20050293A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2004000206A PE20040959A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi y procedimientos para su preparacion
PE2004000203A PE20050292A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos

Country Status (34)

Country Link
US (5) US7365084B2 (US07365084-20080429-C00036.png)
EP (3) EP1599453B1 (US07365084-20080429-C00036.png)
JP (3) JP2006519199A (US07365084-20080429-C00036.png)
KR (3) KR20050106461A (US07365084-20080429-C00036.png)
CN (3) CN100398526C (US07365084-20080429-C00036.png)
AR (3) AR043432A1 (US07365084-20080429-C00036.png)
AT (3) ATE435217T1 (US07365084-20080429-C00036.png)
AU (3) AU2004215673B2 (US07365084-20080429-C00036.png)
BR (3) BRPI0407907A (US07365084-20080429-C00036.png)
CA (3) CA2516620A1 (US07365084-20080429-C00036.png)
CL (2) CL2004000392A1 (US07365084-20080429-C00036.png)
CO (2) CO5690578A2 (US07365084-20080429-C00036.png)
DE (4) DE10308355A1 (US07365084-20080429-C00036.png)
DK (3) DK1599452T3 (US07365084-20080429-C00036.png)
EC (2) ECSP055985A (US07365084-20080429-C00036.png)
ES (3) ES2287700T3 (US07365084-20080429-C00036.png)
HR (3) HRP20050744A2 (US07365084-20080429-C00036.png)
IL (2) IL170314A (US07365084-20080429-C00036.png)
MA (3) MA27737A1 (US07365084-20080429-C00036.png)
MX (3) MXPA05008995A (US07365084-20080429-C00036.png)
NO (3) NO20054398L (US07365084-20080429-C00036.png)
OA (2) OA13034A (US07365084-20080429-C00036.png)
PA (1) PA8596801A1 (US07365084-20080429-C00036.png)
PE (3) PE20040959A1 (US07365084-20080429-C00036.png)
PL (3) PL378130A1 (US07365084-20080429-C00036.png)
PT (3) PT1599452E (US07365084-20080429-C00036.png)
RS (1) RS20050594A (US07365084-20080429-C00036.png)
RU (3) RU2005129995A (US07365084-20080429-C00036.png)
SA (1) SA04250153A (US07365084-20080429-C00036.png)
TN (2) TNSN05206A1 (US07365084-20080429-C00036.png)
TW (3) TW200510352A (US07365084-20080429-C00036.png)
UY (2) UY28210A1 (US07365084-20080429-C00036.png)
WO (3) WO2004076427A1 (US07365084-20080429-C00036.png)
ZA (2) ZA200505765B (US07365084-20080429-C00036.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
EP2052728B1 (en) 2006-08-10 2018-06-13 mimozax Co., Ltd. Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia
CN105732376A (zh) 2007-08-16 2016-07-06 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
WO2009107799A1 (ja) * 2008-02-29 2009-09-03 日産化学工業株式会社 チオフェン化合物及びその中間体の製造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116184785A (zh) 2017-12-13 2023-05-30 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
EP0958296B1 (en) 1996-12-31 2003-07-30 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
EP1067109B1 (en) * 1998-03-10 2009-12-09 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
PT1177176E (pt) * 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
SK15532001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s dvoma arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
WO2001004146A2 (en) 1999-07-09 2001-01-18 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
DK1204654T3 (da) 1999-07-29 2003-11-17 Lilly Co Eli Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
DK1218341T3 (da) 1999-09-01 2005-12-12 Sanofi Aventis Deutschland Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
EE200200278A (et) 1999-12-03 2003-06-16 Astrazeneca Ab (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe kristalne vorm
CA2400226C (en) 2000-03-31 2007-01-02 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
WO2001081327A1 (fr) 2000-04-25 2001-11-01 Kyorin Pharmaceutical Co., Ltd. Nouveau cristal stable de derive thiazolidinedione et son procede de production
CA2407538C (en) 2000-04-28 2007-01-09 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
DE50102147D1 (de) 2000-06-09 2004-06-03 Aventis Pharma Gmbh Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
ATE361283T1 (de) * 2000-08-23 2007-05-15 Lilly Co Eli Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU1609702A (en) 2000-12-21 2002-07-01 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
BR0116526A (pt) * 2000-12-25 2004-07-06 Ono Pharmaceutical Co Compostos derivados do diidronaftaleno e agentes compreendendo o derivado como componente ativo
BR0207285A (pt) 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
JP2005502600A (ja) * 2001-06-07 2005-01-27 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体(ppar)のモジュレーター
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
KR100915108B1 (ko) 2001-08-31 2009-09-03 사노피-아벤티스 도이칠란트 게엠베하 Ppar-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
EP1599453B1 (de) 2009-05-06
ES2326418T3 (es) 2009-10-09
NO20054396D0 (no) 2005-09-22
ES2329366T3 (es) 2009-11-25
US7365084B2 (en) 2008-04-29
SA04250153A (ar) 2005-12-03
WO2004076428A1 (de) 2004-09-10
RU2005129995A (ru) 2006-01-27
NO20054398D0 (no) 2005-09-22
ATE435217T1 (de) 2009-07-15
DE502004009453D1 (de) 2009-06-18
IL170314A (en) 2010-11-30
JP2006519194A (ja) 2006-08-24
OA13034A (en) 2006-11-10
RS20050594A (en) 2007-12-31
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
JP2006519199A (ja) 2006-08-24
UY28209A1 (es) 2004-09-30
PT1599452E (pt) 2007-09-12
PE20040959A1 (es) 2005-01-17
WO2004076427A1 (de) 2004-09-10
BRPI0407814A (pt) 2006-02-14
AU2004215672B2 (en) 2010-01-07
AU2004215677B2 (en) 2010-01-07
TW200500349A (en) 2005-01-01
CA2517386A1 (en) 2004-09-10
MXPA05008995A (es) 2005-10-18
CN100439347C (zh) 2008-12-03
CN1753879A (zh) 2006-03-29
EP1599453A1 (de) 2005-11-30
CN1756748A (zh) 2006-04-05
KR20050106462A (ko) 2005-11-09
EP1599452B1 (de) 2007-06-20
UY28210A1 (es) 2004-09-30
AU2004215673B2 (en) 2009-10-01
ATE430738T1 (de) 2009-05-15
ECSP055985A (es) 2006-01-16
MXPA05008988A (es) 2005-10-18
PT1599455E (pt) 2009-09-29
RU2005130002A (ru) 2006-01-27
CA2517381A1 (en) 2004-09-10
DK1599452T3 (da) 2007-10-01
KR20050105492A (ko) 2005-11-04
AR043433A1 (es) 2005-07-27
DK1599453T3 (da) 2009-08-24
JP2006519193A (ja) 2006-08-24
TNSN05204A1 (en) 2007-06-11
HRP20050744A2 (en) 2006-09-30
CN100439345C (zh) 2008-12-03
ATE365159T1 (de) 2007-07-15
PT1599453E (pt) 2009-07-14
AR043427A1 (es) 2005-07-27
DE502004004139D1 (de) 2007-08-02
TW200510352A (en) 2005-03-16
US7335671B2 (en) 2008-02-26
CL2004000392A1 (es) 2005-04-22
AR043432A1 (es) 2005-07-27
ECSP055986A (es) 2006-01-16
WO2004076426A1 (de) 2004-09-10
TW200508210A (en) 2005-03-01
BRPI0407907A (pt) 2006-02-14
AU2004215677A1 (en) 2004-09-10
PL378437A1 (pl) 2006-04-03
US20040209920A1 (en) 2004-10-21
MA27737A1 (fr) 2006-02-01
PE20050292A1 (es) 2005-05-24
CO5690578A2 (es) 2006-10-31
CN100398526C (zh) 2008-07-02
ZA200505768B (en) 2005-11-23
DK1599455T3 (da) 2009-11-09
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
US20050215596A1 (en) 2005-09-29
PL377735A1 (pl) 2006-02-20
CL2004000391A1 (es) 2005-01-07
US7259177B2 (en) 2007-08-21
PL378130A1 (pl) 2006-03-06
US20080167354A1 (en) 2008-07-10
EP1599455B1 (de) 2009-07-01
BRPI0407758A (pt) 2006-02-14
US20050101637A1 (en) 2005-05-12
MA27742A1 (fr) 2006-02-01
CA2516620A1 (en) 2004-09-10
US20080015238A1 (en) 2008-01-17
OA13035A (en) 2006-11-10
NO20054396L (no) 2005-11-11
NO20054398L (no) 2005-11-02
CO5690580A2 (es) 2006-10-31
DE502004009690D1 (de) 2009-08-13
AU2004215673A1 (en) 2004-09-10
ES2287700T3 (es) 2007-12-16
NO20054408D0 (no) 2005-09-22
CN1753881A (zh) 2006-03-29
TNSN05206A1 (en) 2007-06-11
RU2005129992A (ru) 2006-02-10
US7872034B2 (en) 2011-01-18
AU2004215672A1 (en) 2004-09-10
ZA200505765B (en) 2006-05-31
DE10308355A1 (de) 2004-12-23
EP1599452A1 (de) 2005-11-30
MA27736A1 (fr) 2006-02-01
EP1599455A1 (de) 2005-11-30
HRP20050742A2 (en) 2006-09-30
KR20050106461A (ko) 2005-11-09
MXPA05008951A (es) 2005-11-04

Similar Documents

Publication Publication Date Title
PE20050293A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
AR078756A1 (es) Moduladores alostericos positivos (map)
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR047085A1 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
PE20040349A1 (es) Beta-aminoacidos con afinidad por la proteina alfa-2-delta
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
RU2015125591A (ru) БЕНЗИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ RORc
PE20081504A1 (es) Compuestos de biciclocarboxiamida sustituidos
AR057887A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
PE20140968A1 (es) Derivados de benzamida sustituida
PE20090548A1 (es) Compuestos aza-biciclohexano como inhibidores de trombina
AR065904A1 (es) Heterociclos como antagonistas de orexina
AR075160A1 (es) Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa

Legal Events

Date Code Title Description
FC Refusal